FDA Ticks Extra Patent Time for ADBRY Drug
Published Date: 5/14/2025
Notice
Summary
The FDA has officially set the review period for ADBRY, a human biological product, so its patent can be extended. This helps the company get extra time to protect their invention after the long approval process. If you’re involved in biotech or patents, this means the clock just got a little longer for ADBRY’s patent rights!
No Economic Impacts Identified for this Document
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-19419, Sanjay Kumar: Final Debarment Order
Sanjay Kumar is banned for 5 years from importing any drugs into the U.S. because he was convicted of a serious crime involving fake goods. He didn’t respond to the FDA’s notice, so the ban starts on September 23, 2026. He can apply to end the ban anytime, but must follow special rules to keep info private.
2026-19349, Nonclinical Testing Terminology
The FDA wants to update its rules by swapping out the word “animal” tests for “nonclinical” tests to better reflect modern science. This change affects drug safety testing rules, encourages new testing methods that might use fewer animals, and doesn’t add any new costs or requirements. Anyone interested can comment on these changes until December 7, 2026.
Previous / Next Documents
Previous: 2025-08460, Meeting of Humanities Panel
The National Endowment for the Humanities is hosting three video meetings in May 2025 to review and recommend funding for arts and humanities projects. If you’ve applied for financial help, these meetings decide who gets the money. This means your project could get a boost soon, so keep an eye out!
Next: 2025-08463, Notice of Public Meeting of the New Mexico Advisory Committee to the U.S. Commission on Civil Rights
The New Mexico Advisory Committee to the U.S. Commission on Civil Rights is holding online meetings to review their report on immigrant detention centers in New Mexico. These meetings affect community members interested in civil rights and immigration issues. No costs or changes are announced yet, but the meetings are happening soon via ZoomGov.